NV-128 / Lite Strategy, Kazia - LARVOL DELTA

ME128 - The returned traveler with eosinophilia: clinical, diagnostic and therapeutic approaches (ESCMID Global 2026) - "This is particularly important for diseases with eosinophilia, whose diagnostic and therapeutic approach is usually challenging. At the end of the session, the participants will be able to understand the clinical presentation, diagnostic tools, and treatment options of challenging tropical medicine cases that present with eosinophilia."

Clinical • Eosinophilia • Infectious Disease

Comprehensive analysis the role of cuproptosis related genes in abdominal aortic aneurysm. (PubMed, Ann Med Surg (Lond)) - "Eight NDUF subunits, including NDUFA1, NDUFA4, and NDUFB1, may also play an important role in this process. In addition, Metformin, ME-344 and NV-128 may be therapeutic agents for AAA by regulating the cuproptosis."

Journal • Cardiovascular • CD4 • CDKN2A • FDX1 • LIPT1 • NDUFB1

ME128 - How to apply organoid models to study infectious disease (ESCMID Global 2025) - "These tools offer exciting insights into host-pathogen interactions and therapeutic applications at a molecular level. In this MTE, both the application of organoid models in molecular biology and their clinical use to study and combat infectious diseases, including their potential to advance personalised medicine, will be presented."

Infectious Disease

Correlation of disulfidptosis and periodontitis: New insights and clinical significance. (PubMed, Arch Oral Biol) - "SLC7A11, SLC3A2, RPN1, NCKAP1, LRPPRC, and NDUFS1 are targets associated with disulfidptosis in periodontitis, and ME-344, NV-128, and RILUZOLE are promising agents for the treatment of periodontitis."

Journal • Dental Disorders • Periodontitis • LRPPRC • NDUFS1 • SLC3A2 • SLC7A11

Drug repurposing for rheumatoid arthritis: Identification of new drug candidates via bioinformatics and text mining analysis. (PubMed, Autoimmunity) - "We hypothesize that the FDA-approved drugs momelotinib, ibrutinib, and sodium butyrate may be promising candidates for RA. In addition, CHEMBL306380, Compound 19a (CHEMBL3116050), ME-344, XL-019, TG100801, JNJ-26483327, and NV-128 were identified as novel repurposing candidates for the treatment of RA. Preclinical and further validation of these drugs may provide new treatment options for RA."

Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology